What is sundown syndrome in elderly patients with dementia and how should it be managed?

Sundown Syndrome in Elderly Patients with Dementia

Definition and Clinical Presentation

Sundown syndrome (also called sundowning) is the emergence or worsening of neuropsychiatric symptoms—including agitation, confusion, anxiety, aggression, irritability, and restlessness—occurring specifically in the late afternoon, early evening, or at night in patients with dementia. 1, 2, 3

The syndrome affects approximately 21% of dementia patients attending memory clinics, though prevalence estimates range widely from 1.6% to 66% depending on the population studied 3, 4. The most common manifestations are agitation (56%), irritability (54%), and anxiety (46%) 3.

Sundowning is associated with more severe cognitive impairment (higher Clinical Dementia Rating scores), greater functional decline, more frequent nocturnal awakenings, and hearing loss 3. It leads to faster cognitive deterioration, increased caregiver burden, and earlier institutionalization 1.

Pathophysiology

The underlying mechanisms involve degeneration of the suprachiasmatic nucleus (SCN) in the hypothalamus, which controls circadian rhythms 5, 2. Alzheimer's disease causes a loss of neurons within the SCN, disrupting the generation and maintenance of normal sleep-wake cycles 5. This neurodegeneration leads to decreased melatonin production and reduced amplitude of circadian rhythms 2.

Additional contributing factors include inadequate daytime light exposure, reduced participation in physical and social activities, and environmental factors that fail to provide adequate zeitgebers (time-giving cues) 5.

---

Management Approach

Step 1: Non-Pharmacological Interventions (MANDATORY FIRST-LINE)

All patients with sundowning must receive intensive non-pharmacological interventions before any medication is considered, as these have substantial evidence for efficacy without the mortality risks associated with pharmacological approaches. 6, 7

Bright Light Therapy (Primary Intervention)

• Provide 2 hours of morning bright light exposure at 3,000–5,000 lux, positioned approximately 1 meter from the patient's eyes, between 9:00–11:00 AM, continued for 4–10 weeks 6, 5
• This consolidates nighttime sleep, decreases daytime napping, reduces agitated behavior, and increases circadian rhythm amplitude 6, 5
• Avoid bright light exposure in the evening, as this disrupts the sleep-wake cycle 5
• Ensure adequate lighting during late afternoon hours (when sundowning typically peaks) to reduce visual misinterpretations and confusion 6, 7

Structured Daily Activities

• Establish consistent times for exercise, meals, and bedtime to regulate disrupted circadian rhythms 6, 7
• Provide at least 30–60 minutes of total daily physical activity distributed throughout the day, including 5–30 minute walking sessions 6
• Schedule activities earlier in the day when the patient is most alert, avoiding overstimulation in late afternoon 6
• Maximize daytime sunlight exposure (at least 30 minutes daily) and structured physical and social activities during daylight hours 6, 7

Environmental Modifications

• Reduce nighttime light and noise while maintaining sufficient illumination to prevent confusion 6, 5
• Remove environmental hazards including slippery floors, throw rugs, and obtrusive electric cords that become more dangerous when evening confusion worsens 6
• Use calendars, clocks, color-coded labels, and orientation cues to minimize confusion 6
• Simplify the environment by reducing clutter and avoiding overstimulation 6

Communication and Behavioral Strategies

• Use the "three R's" (repeat, reassure, redirect) when agitation begins rather than confrontation 6
• Employ calm tones, simple one-step commands, and gentle touch for reassurance 6, 7
• Allow adequate time for the patient to process information before expecting a response 6
• Implement scheduled toileting or prompted voiding to reduce incontinence-related agitation 6

Caregiver Education

• Educate caregivers that behaviors are symptoms of dementia, not intentional actions, to promote empathy and understanding 6, 7

---

Step 2: Investigate and Treat Reversible Medical Causes

Before considering any medication, systematically evaluate and treat:

• Infections (urinary tract infections, pneumonia) 6, 8
• Pain (a major contributor to behavioral disturbances in patients who cannot verbally communicate discomfort) 6, 8
• Metabolic disturbances (dehydration, electrolyte abnormalities, hypoxia, hyperglycemia) 6, 8
• Constipation and urinary retention 6, 8
• Medication side effects, especially anticholinergic agents that worsen confusion and agitation 6, 8
• Hearing and vision impairments that increase confusion and fear 6, 8

---

Step 3: Pharmacological Options (ONLY After Non-Pharmacological Failure)

Critical Safety Warning

The American Academy of Sleep Medicine provides a STRONG AGAINST recommendation for sleep-promoting medications in elderly dementia patients due to significantly increased risks of falls, cognitive decline, confusion, and mortality that outweigh any potential benefits. 6

Melatonin (NOT Recommended)

• The American Academy of Sleep Medicine provides a WEAK AGAINST recommendation for melatonin in elderly dementia patients with irregular sleep-wake rhythm disorder 6
• High-quality trials show no improvement in total sleep time, with potential harm including detrimental effects on mood and daytime functioning 6
• Evidence is inconsistent: one trial found no significant difference at 2.5 mg, with only a non-significant trend toward improvement at 10 mg 5, 7
• Do not combine light therapy with melatonin in demented elderly patients 6

Cholinesterase Inhibitors (Consider if Not Already Prescribed)

• If not already prescribed, initiate a cholinesterase inhibitor for cognitive symptoms, as these medications can also reduce behavioral and psychopathologic symptoms including sundowning 6
• Donepezil 10 mg daily or rivastigmine up to 6 mg twice daily may help with agitation associated with sundowning 6
• Start low and titrate slowly: donepezil 5 mg daily for 4–6 weeks before increasing to 10 mg; rivastigmine 1.5 mg twice daily with food, increasing every 4 weeks to maximum 6 mg twice daily 6

SSRIs (First-Line Pharmacological Option for Chronic Agitation)

• Use selective serotonin reuptake inhibitors (citalopram 10–40 mg daily or sertraline 25–200 mg daily) as first-line if depression or chronic agitation contributes to evening behavioral symptoms 6, 8
• SSRIs have minimal anticholinergic effects and significantly reduce agitation compared to placebo (mean difference -0.89 on CMAI scores) 6
• Allow 4–8 weeks for full therapeutic effect at adequate dosing 6, 8
• Assess response after 4 weeks; if no clinically significant improvement, taper and withdraw 6, 8

Antipsychotics (LAST RESORT ONLY)

• Reserve atypical antipsychotics only for severe, dangerous symptoms (delusions, hallucinations, severe psychomotor agitation, combativeness) that have not responded to all other measures 6, 8
• All antipsychotics increase mortality risk 1.6–1.7 times higher than placebo in elderly dementia patients; this must be discussed with surrogate decision makers before initiation 6, 8
• If absolutely necessary: risperidone starting 0.25 mg at bedtime (maximum 2–3 mg daily) or olanzapine starting 2.5 mg at bedtime (maximum 10 mg daily) 6, 8
• Use the lowest effective dose for the shortest possible duration, with daily in-person evaluation 6, 8
• Attempt taper within 3–6 months to determine if continued medication is necessary 6, 8

---

Critical Pitfalls to Avoid

• Do not jump to antipsychotics first—they carry significant mortality risk and should be reserved only for dangerous behaviors unresponsive to all other interventions 6
• Do not ignore underlying medical issues such as pain, infection, constipation, or medication side effects that can worsen evening agitation 6
• Do not use benzodiazepines—they increase delirium incidence and duration, cause paradoxical agitation in approximately 10% of elderly patients, and worsen cognitive function 6, 8
• Do not continue medications indefinitely without reassessment; review need at every visit and taper if no longer indicated 6, 8